Onconova Therapeutics, Inc. Files 2023 Annual Report (10-K)

TL;DR

<b>Onconova Therapeutics, Inc. has submitted its 2023 10-K annual report detailing its financial and operational status.</b>

AI Summary

Onconova Therapeutics, Inc. (TRAW) filed a Annual Report (10-K) with the SEC on April 1, 2024. Onconova Therapeutics, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period up to December 31, 2023, with a filing date of April 1, 2024. The company's principal business address is 375 Pheasant Run, Newtown, PA 18940. Onconova Therapeutics, Inc. is classified under the SIC code 2834 for Pharmaceutical Preparations. The report details various financial and operational aspects of the company for the fiscal year 2023.

Why It Matters

For investors and stakeholders tracking Onconova Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Onconova's financial performance, strategic initiatives, and risk factors for the fiscal year 2023, crucial for investors assessing the company's current standing and future prospects. The detailed information within the report, including financial statements and business descriptions, is essential for stakeholders to understand the company's operations, regulatory compliance, and market position within the pharmaceutical preparations industry.

Risk Assessment

Risk Level: medium — Onconova Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated pharmaceutical industry, facing risks related to drug development, clinical trials, and market approval, which can significantly impact its financial performance and stock value.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to assess the viability of Onconova's drug pipeline and its ability to achieve profitability.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-01 — Filing Date (Date of submission)
• 2834 — SIC Code (Industry classification)

Key Players & Entities

• Onconova Therapeutics, Inc. (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-04-01 (date) — Filing date
• 375 Pheasant Run, Newtown, PA 18940 (address) — Business address
• 2834 (sic_code) — Standard Industrial Classification
• TRAW (ticker) — Ticker symbol

FAQ

Industry Context

Onconova Therapeutics operates within the pharmaceutical preparations industry, focusing on the development of novel therapeutics for cancer.

Regulatory Implications

The pharmaceutical industry is subject to stringent regulations from bodies like the FDA, impacting drug development, approval processes, and market access.

What Investors Should Do

1. Analyze the company's financial statements for revenue, net income, and cash flow for FY2023.
2. Review the 'Risk Factors' section for potential challenges in drug development and market penetration.
3. Examine any disclosed executive compensation details and their relation to company performance.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-04-01: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 2023 10-K filing; comparison with prior filings will require access to those documents.

Filing Documents

• tmb-20231231x10k.htm (10-K) — 1571KB
• tmb-20231231xex21d1.htm (EX-21.1) — 3KB
• tmb-20231231xex23d1.htm (EX-23.1) — 14KB
• tmb-20231231xex31d1.htm (EX-31.1) — 14KB
• tmb-20231231xex31d2.htm (EX-31.2) — 14KB
• tmb-20231231xex32d1.htm (EX-32.1) — 7KB
• tmb-20231231xex32d2.htm (EX-32.2) — 7KB
• tmb-20231231xex97.htm (EX-97) — 39KB
• 0001558370-24-004525.txt (&nbsp;) — 6406KB
• tmb-20231231.xsd (EX-101.SCH) — 44KB
• tmb-20231231_cal.xml (EX-101.CAL) — 45KB
• tmb-20231231_def.xml (EX-101.DEF) — 144KB
• tmb-20231231_lab.xml (EX-101.LAB) — 394KB
• tmb-20231231_pre.xml (EX-101.PRE) — 298KB
• tmb-20231231x10k_htm.xml (XML) — 949KB

Business

Business 3 Item 1A:

Risk Factors

Risk Factors 30 Item 1B: Unresolved Staff Comments 48 Item 1C: Cybersecurity 48 Item 2:

Properties

Properties 49 Item 3:

Legal Proceedings

Legal Proceedings 49 Item 4: Mine Safety Disclosures 49 PART II 50 Item 5: Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 50 Item 6: Reserved 50 Item 7:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A:

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 57 Item 8:

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 57 Item 9: Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 57 Item 9A:

Controls and Procedures

Controls and Procedures 58 Item 9B: Other Information 58 Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 59 PART III 60 Item 10: Directors, Executive Officers and Corporate Governance 60 Item 11:

Executive Compensation

Executive Compensation 60 Item 12:

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 60 Item 13: Certain Relationships and Related Transactions, and Director Independence 60 Item 14: Principal Accounting Fees and Services 60 PART IV 61 Item 15: Exhibits, Financial Statement Schedules 61 Item 16: Form 10-K Summary 61 i Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K (Annual Report) includes forward-looking statements. We may, in some cases, use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements appear in a number of places throughout this Annual Report and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, protection of our intellectual property portfolio, the degree of clinical utility of our products, particularly in specific patient populations, our ability to develop commercial and manufacturing functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe

BUSINESS

ITEM 1. BUSINESS Overview Onconova Therapeutics, Inc., sometimes referred to as "we" or the "Company," is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. We have proprietary molecularly targeted agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. We believe that the product candidates in our pipeline have the potential to be efficacious in a variety of cancers with unmet medical need. We have the following two clinical-stage programs: (1) narazaciclib (ON 123300), a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and (2) rigosertib administered alone or in combination for investigation in various cancers. We are currently evaluating compounds for in-licensing opportunities. Product Candidates / Compounds Narazaciclib (ON 123300)—Differentiated Multi-Kinase Inhibitor Targeting CDK4/6 Pursuant to a license agreement with Temple University dated January 1, 1999, as amended March 21, 2013 (the Temple Licensing Agreement), we licensed compounds from Temple University including our product candidate narazaciclib. Narazaciclib is a multi-targeted kinase inhibitor targeting multiple cyclin-dependent kinases, (CDK's), AMP-activated protein kinase (AMPK) related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases believed to drive tumor cell proliferation, survival and metastasis. As an apoptotic and antiproliferative agent, narazaciclib modulates the levels and activities of regulatory proteins of the cell cycle, including cyclin D1 and inhibits retinoblastoma (Rb) protein binding. Narazaciclib is believed to inhibit cancer cell growth and suppresses deoxyribonucleic acid (DNA) synthesis by preventing CDK-mediated G1-S phase transition, followed by tumor cell deat

View Full Filing

View this 10-K filing on SEC EDGAR